A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

References

• Xarelto^® (rivaroxaban) [prescribing information]Leverkusen, GermanyBayer Healthcare AG2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdfAccessed February 6, 2013
   Google Scholar
• Eliquis^® (apixaban) tablets [prescribing information]New YorkBristol-Myers Squibb Company2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdfAccessed January 24, 2013
   Google Scholar
• FrostCWangJNepalSApixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBr J Clin Pharmacol201375247648722759198
   PubMed Web of Science ®Google Scholar
• StampfussJKubitzaDBeckaMMueckWThe effect of food on the absorption and pharmacokinetics of rivaroxabanInt J Clin Pharmacol Ther201351754956123458226
   PubMed Web of Science ®Google Scholar
• Xarelto^® (rivaroxaban). Summary of product characteristicsLeverkusen, GermanyBayer Pharma AG Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed May 24, 2012
   Google Scholar
• Eliquis^® (apixaban) tablets. Summary of product characteristicsNew YorkBristol-Myers Squibb Pfizer EEIG Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed June 2, 2013
   Google Scholar
• FrostCNepalSWangJSafety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjectsBr J Clin Pharmacol201376577678623451769
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• BarrettYCWangZFrostCShenkerAClinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayThromb Haemost201010461263127120978714
   PubMed Web of Science ®Google Scholar
• UpretiVVWangJBarrettYCEffect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjectsBr J Clin Pharmacol201376690891623488672
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMZuehlsdorfMMueckWEffect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjectsJ Clin Pharmacol200646554955816638738
   PubMed Web of Science ®Google Scholar
• MueckWBorrisLCDahlOEPopulation pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementThromb Haemost2008100345346118766262
   PubMed Web of Science ®Google Scholar
• CuiYSongYWangJSingle- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjectsClin Pharmacol2013517718424353445
   PubMedGoogle Scholar
• YamahiraNFrostCFukaseHSafety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjectsInt J Clin Pharmacol Ther201452756457324725442
   PubMed Web of Science ®Google Scholar
• LeilTAFengYZhangLPaccalyAMohanPPfisterMQuantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial doseClin Pharmacol Ther201088337538220686477
   PubMed Web of Science ®Google Scholar
• LassenMRDavidsonBLGallusAPineoGAnsellJDeitchmanDThe efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJ Thromb Haemost20075122368237517868430
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCDahlOEODIXa-HIP Study InvestigatorsA once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacementCirculation2006114222374238117116766
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLDahlOEODIXa-HIP Study InvestigatorsOral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacementJ Thromb Haemost20064112112816409461
   PubMed Web of Science ®Google Scholar
• TurpieAGFisherWDBauerKAOdiXa-Knee Study GroupBAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJ Thromb Haemost20053112479248616241946
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCDahlOEDose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacementThromb Res2007120568569317292948
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRECORD1 Study GroupRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med2008358262765277518579811
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med2009361659460419657123
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOERECORD2 InvestigatorsExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet20083729632313918582928
   PubMed Web of Science ®Google Scholar
• LassenMRAgenoWBorrisLCRECORD3 InvestigatorsRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med2008358262776278618579812
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDHornickPADVANCE-2 investigatorsApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialLancet2010375971780781520206776
   PubMed Web of Science ®Google Scholar
• LassenMRGallusARaskobGEPineoGChenDRamirezLMADVANCE-3 InvestigatorsApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med2010363262487249821175312
   PubMed Web of Science ®Google Scholar
• TurpieAGLassenMRDavidsonBLRECORD4 InvestigatorsRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialLancet200937396761673168019411100
   PubMed Web of Science ®Google Scholar